Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (16611)	3/6/1998 3:29:00 PM
From: Hippieslayer	Respond to of 32384

Here's some news that finally deals with lgnd. Enjoy. biz.yahoo.com

To: Henry Niman who wrote (16611)	3/6/1998 3:33:00 PM
From: J Stone	Read Replies (1) \| Respond to of 32384

Henry et al: This just out: Scherer Discloses Two New Softgel Products in its Pipeline TROY, Mich.--(BW HealthWire)--March 6, 1998--R.P. Scherer today announced that it was collaborating with its customer, Ligand Pharmaceuticals Inc. (NASDAQ:LGND), on Ligand's Panretin(TM) (LGD1057) and Targretin(TM) (LGD1069) Oral Capsules. Panretin(TM) Oral Capsules and Targretin(TM) Oral Capsules are softgel formulations within a new category of drug products called "retinoids," thought to be useful in the treatment of various cancers, dermatological diseases, and metabolic diseases. The softgel formulations for these Ligand products were jointly developed by Ligand and R.P. Scherer in a project dating to January 1993 and are expected to be commercialized in 1999 and 2000. Panretin(TM) Oral Capsules are in single-agent Phase II trials and in a Phase I trial in combination with interferon for patients with AIDS-related Kaposi's sarcoma. Phase II trials are ongoing in breast, ovarian, and pediatric cancers, bronchial metaplasia and myelodysplastic syndrome, and a study in severe plaque psoriasis has been completed. Targretin(TM) Oral Capsules are in Phase II/III registration trials for cutaneous T-Cell lymphoma and in ongoing Phase II trials for type II diabetes, head and neck, lung, ovarian and prostate cancers, systemic Kaposi's sarcoma and Psoriasis. R.P. Scherer Corporation, an international developer and manufacturer of drug delivery systems, is the world's largest producer of soft gelatin capsules ("softgels"). The Company is currently developing and commercializing a variety of advanced drug delivery systems, including Zydis(R), PassCal(TM) and R.P. Scherersol(R) technologies. The Company's proprietary drug delivery systems improve the efficacy of drugs by regulating the dosage so as to ease administration, increase absorption, enhance bioavailability and control the time and place of release. The Company operates a global network of 19 facilities in 12 countries. Except for the historical information contained herein, the matters discussed in this presentation are forward looking statements that involve risks and uncertainties, including whether the disclosed products can be successfully formulated, scaled-up, developed and commercialized, whether regulatory approvals can be obtained and the impact of competitive products and pricing. These forward looking statements represent R.P. Scherer's judgment as of the date this information was prepared. Panretin(TM) and Targretin(TM) are trademarks of Ligand Pharmaceuticals Inc. Zydis, PassCal and R.P. Scherersol are trademarks of R.P. Scherer Corporation. To obtain copies of the Company's earnings and press releases, or to request copies of the annual report or SEC filings, please visit our web site at www.rpscherer.com or call the Company's toll-free shareholder information line, 888-SHR-NEWS, from the U.S., Canada and most of the Caribbean. From outside the U.S. or Canada, please call the Company directly. CONTACT: R.P. Scherer Corporation Nicole Williams, 248/649-0900 Fax: 248/649-2079 15:02 EST MARCH 6, 1998

To: Henry Niman who wrote (16611)	3/6/1998 3:36:00 PM
From: Mudcat	Respond to of 32384

Lgnd News biz.yahoo.com I was not sure how to post the site.

To: Henry Niman who wrote (16611)	3/6/1998 4:04:00 PM
From: Abuckatatime	Read Replies (4) \| Respond to of 32384

Henry, re: <<implications for oral version of GM-CSF are very strong>>. Agreed. And exciting. IMNX's Leukine, an injectible GM-CSF, is used following chemo in acute myelogenous leukemia, in accelerating recovery following marrow transplantation (eg for treatment of cancer), and has been shown to lengthen survival of melanoma patients. It may have other indications as well, I'm not sure. Looks like an oral GM-CSF could tap into a sizeable market. Anyone know what revenues Leukine generates for IMNX? Greg